Esperion Therapeutics, Inc. — Director's Dealing 2021

Jan 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2021-01-28

Reporting Person: Koenig Sheldon L. (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-28	Common Stock	A	30000	—	Acquired	30000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-28	Stock Option (right to buy)	$32.12	A	150000	Acquired	2031-01-28	Common Stock (150000.0)	Direct

Footnotes

F1: Such award will vest over a four (4) year period as follows: 25% shall vest on the one year anniversary of December 15, 2020 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter, subject to continued service.